Hypera (HYPE3.SA) Akcija Kursas

Hypera Kursas

B3·UŽDARTAS
26,94
​
Rinka uždaryta

Per pastaruosius 19 metus Hypera pajamos augo 17,2 % kasmet ir pasiekė 7,70 mlrd. BRL. Pelnas akcijai augo 15,8 % per metus per pastaruosius 18 metus. Hypera grynoji marža 15,5 % yra sumažėjo palyginti su 22,4 % prieš kelerius metus. Esama kaina dividendo pajamingumas yra apie 4,34 %. Išmokų koeficientas yra apie 63 % pelno. Dividendas augo 17,6 % per metus per pastaruosius 14 metus. Hypera 12 mėn. konsensuso tikslinė kaina yra 30,09 BRL, apie virš kursą 11,7 %. Iš 19 analitikų 13 rekomenduoja pirkti — bendras konsensusas yra Pirkti.

Hypera akcijos kaina

Gaukite šiuos duomenis per Eulerpool API

100 000 užklausų/mėn. nemokamai · be kortelės

Hypera akcija ir akcijų analizė

„Hypera SA“ yra Brazilijos farmacijos įmonė, įkurta 2001 m., specializuojasi vaistų, generinių vaistų, medicinos prietaisų ir kosmetikos produktų plėtroje, gamyboje ir platinime, daugiausia skirtuose Brazilijos sveikatos priežiūros sektoriui.

Dažnai užduodami klausimai apie Hypera akciją

Hypera SA, a leading pharmaceutical company based in Brazil, operates on a robust business model. The core of their business involves the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. Hypera SA specializes in both prescription and over-the-counter medications, catering to various therapeutic areas. They also produce medical-hospital products and non-pharmaceutical items such as personal hygiene and beauty care products. With a focus on innovation and quality, Hypera SA aims to improve the health and well-being of individuals across the country. As a prominent player in the pharmaceutical industry, Hypera SA continues to expand its product portfolio, enhance operational efficiency, and ensure customer satisfaction.

Hypera SA is primarily active in the pharmaceutical industry.

The main competitors of Hypera SA in the market are pharmaceutical companies such as Aché Laboratórios, EMS Pharma, and Eurofarma.

Hypera SA, formerly known as Hypermarcas SA, is a leading pharmaceutical company based in Brazil. Founded in 2001, Hypera has a rich history and has significantly grown over the years. It focuses on the development, production, and commercialization of pharmaceutical products, generic drugs, over-the-counter medications, and personal care items. Hypera has established a strong presence in the Brazilian market, offering a wide range of high-quality and affordable healthcare solutions. Its commitment to research and innovation has led to numerous successful product launches. Hypera SA continues to be a prominent player in the pharmaceutical industry, continuously expanding its portfolio and enhancing the well-being of consumers.

Hypera SA, a renowned company in the pharmaceutical industry, has accomplished several significant milestones throughout its journey. The company has successfully positioned itself as a leader in the Latin American market, expanding its presence across various countries. Hypera SA has consistently demonstrated its commitment to innovation and research, introducing numerous breakthrough pharmaceutical products. With strategic acquisitions and partnerships, the company has further strengthened its portfolio and market share. Hypera SA's relentless focus on quality control and strict adherence to regulatory standards has earned it a stellar reputation among industry experts and stakeholders. These achievements reflect Hypera SA's dedication to advancing healthcare solutions and driving long-term growth in the pharmaceutical sector.

Hypera SA is primarily present in Brazil.

Hypera SA represents a strong commitment to its corporate philosophy, which revolves around innovation, excellence, and integrity. With a focus on enhancing quality of life, Hypera SA aims to deliver innovative healthcare solutions to consumers. The company puts a strong emphasis on research and development, constantly striving to introduce new and effective products to market. By promoting a culture of excellence, Hypera SA seeks to provide top-notch customer service and quality-assured products. With a dedication to integrity, the company operates transparently and ethically, ensuring trust and reliability among its stakeholders. Hypera SA's values and corporate philosophy ultimately drive its mission to positively impact people's health and well-being.

Analitikai šiuo metu nustato vidutinę Hypera akcijos tikslinę kainą 30,54 BRL (mediana: 30,09 BRL), t. y. +13,4 % palyginti su paskutine kaina. Konsensusas pagrįstas 19 analitikų reitingais.

19 analitikai šiuo metu vertina Hypera akciją: 13 rekomenduoja pirkti, 6 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Hypera gaus 9,23 mlrd. BRL pajamų ir 2,65 BRL pelno akcijai.

Pagal dabartinį kursą Hypera akcija kainuoja 4,77 EUR (26,94 BRL).

Hypera akcija (HYPE3.SA) kotiruojama 2 biržose, įskaitant: B3 (São Paulo) (HYPE3.SA).

The Brazilian company Hypera SA is a leading manufacturer and distributor of pharmaceuticals, dietary supplements, cosmetics, and household products. It has been listed on the stock exchange since 2008 and has built a strong presence in the Brazilian market in recent years. Hypera SA operates in four business segments: Consumer Health, Pharma, Over-the-Counter medicines, and Cosmetics and Skincare products. The Consumer Health division offers a wide range of products such as vitamins, pain relievers, cough and cold medicines, as well as dietary supplements and baby food. Hypera SA's Pharma business includes prescription drugs, including medications for cardiovascular, diabetes, gastroenterology, and oncology patients. Additionally, the company also provides vaccines and medications for respiratory diseases. In the Over-the-Counter medicines segment, the company offers a wide range of non-prescription medications for colds, digestive issues, pain, and allergies. This includes diet and weight loss products, vitamins and minerals, as well as other supplements. Hypera SA also offers a variety of cosmetic and skincare products, including brands like Episol, Hair Fly, Monange, Neostrata, and Assolan. The company also operates a household products division, which includes brands like Vitasay, Tixan, and Blergh. The product range of Hypera SA is diverse, ranging from affordable mass-market products to more expensive premium brands. The company aims to reach a wide range of customers and has specialized in marketing products for the health and beauty segment. It has established relationships with major retail chains as well as pharmacies and other sales locations. Hypera SA strives to integrate innovation and technology into its business model. The company has a research and development team constantly developing and launching new products. It also invests in automation and digitization of its production facilities to improve the efficiency and quality of its products. Overall, Hypera SA's business model is focused on a wide product range and a strong brand presence. The company relies on price competition and innovation to strengthen its market position. As a leading provider of healthcare, cosmetic, and household products in Brazil, the company aims to expand internationally.

tikėtina pelnas Hypera yra 9,23 mlrd. BRL. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.

tikėtina grynasis pelnas Hypera yra 1,70 mlrd. BRL. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.

Kainų ir nuomos santykis (KGV) Hypera šiuo metu yra 10,16. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Hypera akcijos vertę.

Kainų ir pardavimų santykis (KUV) Hypera šiuo metu yra 1,88. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Hypera akcijos įvertinimo metrika.

Eulerpool kokybės balas Hypera yra 6/10.

Hypera ISIN yra BRHYPEACNOR0. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.

Hypera prekybos žymė yra HYPE3.SA. Ši biržos žymė naudojama Hypera akcijoms prekiauti biržoje.

Tikroji vertėTerminal
28,56 BRL
Per/Nepakankamai vertintaTerminal
Teisingai vertinta
Sektorius
Industrija
Farmacijos produktai
Akcijų skaičius
Darbuotojai
Pajamos vienam darbuotojui
863 327,76 BRL
Pajamų augimas Ø5 metai
EBIT augimas Ø5 metai
Grynojo pelno augimas Ø5 metai
Šalis
Brazilija
Valiuta
BRL
Pirminis viešas pasiūlymas
2008-04-16
ISIN
BRHYPEACNOR0
CUSIP
P5230A101
SEDOL
B2QY968
Rinkos kapitalizacija
52 savaičių diapazonas
AAQS
7 / 10
PEG
1,25
P/E santykis
K/P santykise 2026
10,08
K/P santykise 2027
8,54
K/P santykise 2028
7,14
K/P santykise 2029
6,52
K/P santykise 2030
5,82
P/S
K/A santykise
1,88
EV/EBIT
12,80
P/B santykis
1,37
ROE (nuosavo kapitalo grąža)
ROA (turto grąža)
ROCE (grąža iš panaudoto kapitalo)
ROIC (grąža iš investuoto kapitalo)
5,47 %
Dividendas
Dividendų grąža
4,34 %
Numatyta dividendų grąža
3,91 %
Išmokų koeficientas
62,92 %
Dividendų augimas Ø5M
—
Dividendai per metus
4
Dividendai išmokami nuo
10 metų
Dividendai nesmažinti nuo
1 metai
Dividendai padidinti nuo
1 metai
Sumažinimo mokestis
10,00 %
Paskutinį kartą atnaujinta 2026-10-23 19:48

Hypera Pagrindiniai konkurentai

Hypera Biržos simbolis

B3 · HYPE3.SAB3 · HYPE3.SA

Hypera FIGI

HYPE3:BZ · BBG000HWN5K1HYPE3:BS · BBG000HWN5W8HYPE3:BN · BBG000HWN8S7HYPE3BRL:EO · BBG01GWGJ190HYPE3BRL:X2 · BBG01GWGJ1B7HYPE3BRL:XH · BBG01GWGJ1D5HYPE3BRL:XF · BBG01GWGJ1G2HYPE3BRL:XE · BBG01GWGJ1J9HYPE3BRL:XJ · BBG01GWGJ1K7HYPE3BRL:XL · BBG01GWGJ1L6HYPE3BRL:XG · BBG01GWGJ1M5HYPE3BRL:XO · BBG01GWGJ1N4

Visos Hypera pagrindinės charakteristikos ir giluminė analizė

Mūsų akcijų analizė Hypera akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Hypera. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: